Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Fee-for-Service Reimbursement to Be Permitted for Wider Range of High-priced Drugs
August 15, 2011
- SRUVEY
August 15, 2011
- Female Life Expectancy Down Slightly in 2010; First Decline in 5 Years
August 15, 2011
- PMDA to Initiate Clinical Trial Consultation for Orphan Drugs
August 15, 2011
- Takeda Discontinues Development of Anti-obesity Drug in US
August 15, 2011
- Growth in Diabetes Drug Market Driven by DPP-4 Inhibitors in 2010: Yano Research
August 15, 2011
- JPA President Kodama to Explain about Leaked Copy of His Appeal at General Assembly
August 15, 2011
- NCCHD Creates Pediatric Clinical Trial Network of 27 Facilities
August 15, 2011
- MSD Invites Former JPMA Director General as Compliance Adviser
August 15, 2011
- Kowa Obtains Marketing Approval for Pitavastatin in Mexico
August 15, 2011
- Gov't Council Submits 4th Science & Technology Basic Plan
August 15, 2011
- Kyowa Kirin Aims for 70% Increase in Sales for UK Subsidiary ProStrakan by 2013
August 15, 2011
- AZ's New Antiplatelet Agent Ticagrelor Approved by the FDA
August 15, 2011
- Shionogi Completes New Core Research Facility in Toyonaka
August 15, 2011
- Top-100 Product Ranking Affected by Premium, Price Revisions
August 15, 2011
- RoACTEMRA Approved for sJIA in Children 2 Years or Older in Europe
August 15, 2011
- Tella Announces Research Results for Dendritic Cell Vaccine Therapy
August 15, 2011
- Aricept Has Overwhelming Advantage in AD Market in Japan: Mr Honda
August 15, 2011
- Roche's Tarceva Receives Positive Opinion from CHMP for 1st-Line NSCLC Therapy
August 15, 2011
- Korosho Starts Inviting Requests for Approval of Unapproved Drugs/Indications
August 15, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…